Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on December 4, 2009, to report a material definitive agreement related to a significant equity offering. The company entered into an underwriting agreement on December 2, 2009, to sell 11,500,000 shares of common stock at $38.50 per share. Furthermore, the underwriters exercised their option to purchase an additional 1,500,000 shares, bringing the total shares sold to 13,000,000. This offering represents a substantial capital raise for Vertex Pharmaceuticals, likely intended to fund ongoing research and development, clinical trials, or general corporate purposes. Investors should note the substantial dilution that this significant increase in outstanding shares may entail. The filing details the involvement of major underwriters, including Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated, underscoring the breadth and scale of this transaction.
Key Highlights
- 1Vertex Pharmaceuticals entered into an underwriting agreement on December 2, 2009, to sell 11,500,000 shares of common stock.
- 2The public offering price for the shares was set at $38.50 per share.
- 3Underwriters exercised an option to purchase an additional 1,500,000 shares on December 3, 2009.
- 4The total number of shares sold in the offering amounted to 13,000,000.
- 5The offering was conducted through a prospectus supplement dated December 2, 2009, and an accompanying prospectus dated September 17, 2008.
- 6Key underwriters included Goldman, Sachs & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan Securities Inc., and Morgan Stanley & Co. Incorporated.
- 7The filing includes exhibits such as the underwriting agreement and legal opinions.